Viyash Scientific Limited (IN:VIYASH)
:VIYASH
Want to see IN:VIYASH full AI Analyst Report?
VIYASH Stock Chart & Stats
₹210.65
-₹3.94(-2.00%)
At close: 4:00 PM EST
₹210.65
-₹3.94(-2.00%)
Day’s Range― - ―
52-Week Range₹166.20 - ₹269.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)119.95K
Market Cap
₹110.03B
Enterprise Value₹110.24B
Total Cash (Recent Filing)₹722.20M
Total Debt (Recent Filing)₹4.90B
Price to Earnings (P/E)44.7
Beta1.33
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding436,875,500
10 Day Avg. Volume209,903
30 Day Avg. Volume119,946
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.72
Price to Sales (P/S)2.32
P/FCF Ratio61.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9.3
Revenue Forecast (FY)₹38.63B
Bulls Say, Bears Say
Bulls Say
Revenue And Margin ReboundRevenue more than doubled in 2026 while operating margins rose to roughly 12% EBIT and 19% EBITDA. This demonstrates the business can scale profitably across a larger base, supporting more durable cash generation and reinvestment capacity if the trend holds beyond a single year.
Materially Improved Balance SheetLeverage has fallen sharply to about 0.17 in 2026 from ~0.63–0.74 in prior years, materially lowering financial risk. A stronger capital structure enhances flexibility for capex, R&D or selective M&A, and reduces refinancing and solvency pressure across industry cycles.
Strong Multi-period Growth MomentumTop- and bottom-line momentum (reported revenue growth ~70% and EPS growth ~271%) signals accelerating demand and operational recovery. Sustained multi-period growth supports scale economics, improves unit economics, and creates room to invest in specialty capabilities and market share.
Bears Say
Historic Earnings VolatilityThe firm experienced losses in 2023–2024 and material volatility across 2022–2025, indicating execution and demand risk. Such a history weakens predictability of future cash flows and means management must prove sustained, repeatable profitability before earnings are deemed durable.
Weak Cash ConversionFree cash flow remains under ~50% of net income in 2026 and operating cash flow is a small share of revenue, limiting self‑funding ability. Weak cash conversion raises reliance on external financing and heightens sensitivity to working capital or capex swings, reducing earnings resilience.
Margin Stability ConcernsMargins have swung from negative EBIT in 2023–2024 to improvement in 2026, highlighting instability in cost structure or pricing power. This cyclicality implies margins could compress if volumes or pricing weaken, making future profitability and return metrics less predictable.
Viyash Scientific News
VIYASH FAQ
What was Viyash Scientific Limited’s price range in the past 12 months?
Viyash Scientific Limited lowest stock price was ₹166.20 and its highest was ₹269.00 in the past 12 months.
What is Viyash Scientific Limited’s market cap?
Viyash Scientific Limited’s market cap is ₹110.03B.
When is Viyash Scientific Limited’s upcoming earnings report date?
Viyash Scientific Limited’s upcoming earnings report date is Aug 12, 2026 which is in 82 days.
How were Viyash Scientific Limited’s earnings last quarter?
Viyash Scientific Limited released its earnings results on May 19, 2026. The company reported ₹1.17 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.17.
Is Viyash Scientific Limited overvalued?
According to Wall Street analysts Viyash Scientific Limited’s price is currently Overvalued.
Does Viyash Scientific Limited pay dividends?
Viyash Scientific Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Viyash Scientific Limited dividends here
What is Viyash Scientific Limited’s EPS estimate?
Viyash Scientific Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viyash Scientific Limited have?
Viyash Scientific Limited has 436,875,500 shares outstanding.
What happened to Viyash Scientific Limited’s price movement after its last earnings report?
Viyash Scientific Limited reported an EPS of ₹1.17 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.373%.
Which hedge fund is a major shareholder of Viyash Scientific Limited?
Currently, no hedge funds are holding shares in IN:VIYASH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Viyash Scientific Limited
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and is headquartered in Hyderabad, India. Viyash Scientific Limited operates as a subsidiary of CA Harbor Investments.
Technical Analysis
Akums Drugs and Pharmaceuticals Limited
―
Alembic Pharmaceuticals Limited
―
Caplin Point Laboratories Limited
―
Glenmark Life Sciences Limited
―
Strides Pharma Science Ltd
―